慢性淋巴细胞白血病中ibrutinib的真实心血管风险:一项回顾性研究
Jelena Ivanovic1, Vladimir Otasevic1, Ksenija Markovic2
1Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia.
治疗慢性淋巴细胞白血病 (CLL) 的易布鲁替尼可能会导致心脏毒性,特别是在患有心血管疾病的患者中. 密切监测对于管理这些风险和优化患者治疗结果至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 易布鲁替尼是慢性淋巴细胞白血病 (CLL) 的关键治疗方法.
- 心血管毒性是已知的易布鲁替尼治疗的副作用.
- 在CLL患者中评估心脏毒性发生率和危险因素是必不可少的.
研究的目的:
- 为了评估与ibrutinib治疗的CLL患者心脏毒性发生率.
- 在这个人群中确定易布鲁丁尼布诱导心脏毒性的预测因素.
主要方法:
- 在79名接受ibrutinib治疗的CLL患者进行了回顾性队列研究.
- 对患者特征,心血管事件和治疗结果的分析.
- 统计分析以确定心脏毒性风险因素.
主要成果:
- 心脏毒性发生在29.1%的患者中;心房动是最常见的 (10.1%).
- 以前存在的心血管疾病 (HR=2.850) 和高血压史 (HR=7.935) 显著增加了心脏毒性风险.
- 由于心脏毒性作用,易布鲁替尼在9名患者中断治疗.
结论:
- 心血管监测对于接受ibrutinib治疗的CLL患者至关重要,特别是那些患有先前疾病的患者.
- 为了减轻心脏毒性风险,需要个性化治疗和密切跟踪.
- 这些发现强调了在ibrutinib治疗中需要积极主动地进行心血管风险管理.
更多相关视频
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Relative Risk
Bioequivalence studies: Biowaivers
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
